Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Win 58237 is an inhibitor of cyclic nucleotide phosphodiesterase (PDE) (Ki: 170 nM for PDE V), with vasorelaxant activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Win 58237 is an inhibitor of cyclic nucleotide phosphodiesterase (PDE) (Ki: 170 nM for PDE V), with vasorelaxant activity. |
Targets&IC50 | PDE5:ki:170 nM |
In vitro | Win 58237 is a competitive cGMP PDE V inhibitor from canine aorta(Ki : 170 nM). Win 58237 is a potent PDE V inhibitor isolated from vascular tissue (IC50 : 240 nM). It is a relatively less potent calmodulin-sensitive PDE I and cGMP-inhibitable cyclic AMP PDE III inhibitor ; but does inhibit cyclic AMP PDE IV with an IC50 value of approximately 300 nM. Win 58237 possesses vasorelaxant activity in the presence of an intact endothelium or nitric oxide. |
In vivo | In vivo administration of Win 58237, at dosages ranging from 0.3 to 3.0 mg/kg intravenously, reduces mean arterial pressure in conscious spontaneously hypertensive rats, accompanied by a rise in vascular (aortic) cGMP content. Additionally, at a higher dosage of 10 mg/kg intravenously, Win 58237 elevates plasma cGMP levels from a baseline of 6.7 ± 1.0 to 31.4 ± 3.5 fmol/μL. |
Molecular Weight | 295.34 |
Formula | C16H17N5O |
CAS No. | 158001-76-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Win 58237 158001-76-4 Others inhibitor inhibit